Danske Bank A/S Vaxcyte, Inc. Transaction History

Danske Bank A/S

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 19, 2025	BUY	$29.67 - $37.37 $62,307 - $78,477	2,100 New	2,100 $75,000
Q2 2025 Dec 18, 2025	BUY	$28.04 - $37.2 $53,276 - $70,680	1,900 Added 950.0%	2,100 $68,000
Q1 2025 Dec 18, 2025	SELL	$37.76 - $92.13 $71,744 - $175,047	-1,900 Reduced 90.48%	200 $7,000

321

134M

408K

116K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $2.87B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Danske Bank A/S, based on Form 13F filings with the SEC.

Stay updated on Danske Bank A/S with notifications on news.